USP19 and cardiac hypertrophy: By the way, since USP19 inhibits NF‐κB activation by deubiquitinating TAK1 in immune cells,18 and NF‐κB and subsequent transcription of pro‐inflammatory cytokines37 exert inflammatory response on promoting cardiac hypertrophy38, 39, 40 at later stage, we speculated and confirmed that besides affecting cardiac hypertrophy, fibrosis and dysfunction, USP19 lacking in hearts might also affect the inflammatory phenotype manifested as activation of NF‐κB and more generation of pro‐inflammatory cytokines.